The Anticipated Next Season of EGFR Inhibitors

Por Sequist, Lecia V.
Publicado no Oncologist (2015)

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

Por Piotrowska, Zofia, Sequist, Lecia V.
Publicado no Oncologist (2015)

Adjuvant molecularly targeted therapy—epidermal growth factor tyrosine kinase inhibition and beyond

Por Neal, Joel W., Sequist, Lecia V.
Publicado no Transl Lung Cancer Res (2013)

Genetic Changes in Squamous Cell Lung Cancer: A Review

Por Heist, Rebecca S., Sequist, Lecia V., Engelman, Jeffrey A.
Publicado em 2012

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

Por Oser, Matthew G, Niederst, Matthew J, Sequist, Lecia V, Engelman, Jeffrey A
Publicado no Lancet Oncol (2015)

Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET

Por Arvold, Nils D., Heidari, Pedram, Kunawudhi, Anchisa, Sequist, Lecia V., Mahmood, Umar
Publicado no Technol Cancer Res Treat (2015)

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

Por Sequist, Lecia V., Nagrath, Sunitha, Toner, Mehmet, Haber, Daniel A., Lynch, Thomas J.
Publicado no J Thorac Oncol (2009)

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

Por Campo, Meghan, Al-Halabi, Hani, Khandekar, Melin, Shaw, Alice T., Sequist, Lecia V., Willers, Henning
Publicado no Oncologist (2016)

Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Por Goldberg, Sarah B., Oxnard, Geoffrey R., Digumarthy, Subba, Muzikansky, Alona, Jackman, David M., Lennes, Inga T., Sequist, Lecia V.
Publicado em 2013

Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib

Por Nishino, Mizuki, Dahlberg, Suzanne E., Fulton, Linnea E., Digumarthy, Subba R., Hatabu, Hiroto, Johnson, Bruce E., Sequist, Lecia V.
Publicado no Acad Radiol (2016)

Role of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Por Mak, Raymond H., Digumarthy, Subba R., Muzikansky, Alona, Engelman, Jeffrey A., Shepard, Jo-Anne O., Choi, Noah C., Sequist, Lecia V.
Publicado em 2011

FGFR1 amplification in squamous cell carcinoma of the lung

Por Heist, Rebecca S., Mino-Kenudson, Mari, Sequist, Lecia V., Tammireddy, Swathi, Morrissey, Laura, Christiani, David C., Engelman, Jeffrey A., Iafrate, A. John
Publicado em 2012

Reduced erlotinib sensitivity of EGFR mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment

Por Chin, Tan Min, Quinlan, Margaret P., Singh, Anurag, Sequist, Lecia V., Lynch, Thomas J., Haber, Daniel A., Sharma, Sreenath V., Settleman, Jeffrey
Publicado em 2008

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

Por Eichler, April F., Kahle, Kristopher T., Wang, Daphne L., Joshi, Victoria A., Willers, Henning, Engelman, Jeffrey A., Lynch, Thomas J., Sequist, Lecia V.
Publicado em 2010

The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies

Por Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A.
Publicado no Clin Cancer Res (2015)

Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

Por Lo, Peter C., Dahlberg, Suzanne E., Nishino, Mizuki, Johnson, Bruce E., Sequist, Lecia V., Jackman, David M., Jänne, Pasi A, Oxnard, Geoffrey R.
Publicado no Cancer (2015)

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non–small cell lung cancer treated with radiotherapy for brain metastase...

Por Mak, Kimberley S., Gainor, Justin F., Niemierko, Andrzej, Oh, Kevin S., Willers, Henning, Choi, Noah C., Loeffler, Jay S., Sequist, Lecia V., Shaw, Alice T., Shih, Helen A.
Publicado no Neuro Oncol (2015)

EGFR activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity

Por Pfäffle, Heike N., Wang, Meng, Gheorghiu, Liliana, Ferraiolo, Natalie, Greninger, Patricia, Borgmann, Kerstin, Settleman, Jeffrey, Benes, Cyril H., Sequist, Lecia V., Zou, Lee, Willers, Henning
Publicado em 2013

Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC

Por Mak, Raymond H., Doran, Elizabeth, Muzikansky, Alona, Kang, Josephine, Neal, Joel W., Baldini, Elizabeth H., Choi, Noah C., Willers, Henning, Jackman, David M., Sequist, Lecia V.
Publicado em 2011

Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features

Por Finberg, Karin E., Sequist, Lecia V., Joshi, Victoria A., Muzikansky, Alona, Miller, Julie M., Han, Moonjoo, Beheshti, Javad, Chirieac, Lucian R., Mark, Eugene J., Iafrate, A. John
Publicado em 2007